Cargando…
Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis
SIMPLE SUMMARY: In this bi-institutional analysis including 421 patients, we report an overall high biochemical-recurrence free survival rate (58% after three years) after positron-emission tomography (PET)-based salvage radiotherapy (sRT). Additionally, the strong prognostic effect of prostate spec...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698293/ https://www.ncbi.nlm.nih.gov/pubmed/33207785 http://dx.doi.org/10.3390/cancers12113395 |
_version_ | 1783615797209333760 |
---|---|
author | Schmidt Hegemann, Nina-Sophie Rogowski, Paul Eze, Chukwuka Schäfer, Christian Stief, Christian Lang, Sebastian Spohn, Simon Steffens, Rieke Li, Minglun Gratzke, Christian Schultze-Seemann, Wolfgang Ilhan, Harun Fendler, Wolfgang Peter Bartenstein, Peter Ganswindt, Ute Buchner, Alexander Grosu, Anca-Ligia Belka, Claus Meyer, Philipp Tobias Kirste, Simon Zamboglou, Constantinos |
author_facet | Schmidt Hegemann, Nina-Sophie Rogowski, Paul Eze, Chukwuka Schäfer, Christian Stief, Christian Lang, Sebastian Spohn, Simon Steffens, Rieke Li, Minglun Gratzke, Christian Schultze-Seemann, Wolfgang Ilhan, Harun Fendler, Wolfgang Peter Bartenstein, Peter Ganswindt, Ute Buchner, Alexander Grosu, Anca-Ligia Belka, Claus Meyer, Philipp Tobias Kirste, Simon Zamboglou, Constantinos |
author_sort | Schmidt Hegemann, Nina-Sophie |
collection | PubMed |
description | SIMPLE SUMMARY: In this bi-institutional analysis including 421 patients, we report an overall high biochemical-recurrence free survival rate (58% after three years) after positron-emission tomography (PET)-based salvage radiotherapy (sRT). Additionally, the strong prognostic effect of prostate specific antigen (PSA) level prior to sRT in this patient cohort was observed in multivariate regression analyses. Finally, patients who received staging with two different PET tracers for sRT guidance (cholin vs. prostate specific membrane antigen (PSMA) PET) were compared via propensity score matching and no significant differences in biochemical-recurrent free survival BRFS between the two tracers were observed. ABSTRACT: The purpose of this analysis was primarily to analyze biochemical-recurrence free survival (BRFS) after positron emission tomography (PET)-guided salvage radiotherapy (sRT) in a large cohort, and to further compare BRFS after PSMA vs. choline PET/ computer tomography (CT)-based sRT. This retrospective analysis is based on 421 patients referred for PSMA or choline PET/CT after radical prostatectomy due to biochemically recurrent or persistent disease. BRFS (PSA: 0.2 ng/mL) was defined as the study endpoint. Cox regression analyses were performed to assess the impact of different clinical parameters on BRFS. Additionally, propensity score matching was performed to adjust patient cohorts (PSMA vs. choline PET/CT-based sRT). The median follow-up time was 30 months. BRFS at three years after sRT was 58%. In the multivariate analysis, only PSA before PET imaging and PSA before sRT were significantly associated with BRFS (p < 0.05). After propensity score matching, 272 patients were further analyzed; there was no significant difference in three-year BRFS between patients with PSMA PET-based vs. choline PET-based sRT (55% vs. 63%, p = 0.197). The present analysis confirmed the overall high BRFS rates after PET-based sRT and the strong prognostic effect of PSA level prior to sRT. PSMA PET-based sRT did not have superior BRFS rates when compared with choline PET-based sRT. |
format | Online Article Text |
id | pubmed-7698293 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76982932020-11-29 Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis Schmidt Hegemann, Nina-Sophie Rogowski, Paul Eze, Chukwuka Schäfer, Christian Stief, Christian Lang, Sebastian Spohn, Simon Steffens, Rieke Li, Minglun Gratzke, Christian Schultze-Seemann, Wolfgang Ilhan, Harun Fendler, Wolfgang Peter Bartenstein, Peter Ganswindt, Ute Buchner, Alexander Grosu, Anca-Ligia Belka, Claus Meyer, Philipp Tobias Kirste, Simon Zamboglou, Constantinos Cancers (Basel) Article SIMPLE SUMMARY: In this bi-institutional analysis including 421 patients, we report an overall high biochemical-recurrence free survival rate (58% after three years) after positron-emission tomography (PET)-based salvage radiotherapy (sRT). Additionally, the strong prognostic effect of prostate specific antigen (PSA) level prior to sRT in this patient cohort was observed in multivariate regression analyses. Finally, patients who received staging with two different PET tracers for sRT guidance (cholin vs. prostate specific membrane antigen (PSMA) PET) were compared via propensity score matching and no significant differences in biochemical-recurrent free survival BRFS between the two tracers were observed. ABSTRACT: The purpose of this analysis was primarily to analyze biochemical-recurrence free survival (BRFS) after positron emission tomography (PET)-guided salvage radiotherapy (sRT) in a large cohort, and to further compare BRFS after PSMA vs. choline PET/ computer tomography (CT)-based sRT. This retrospective analysis is based on 421 patients referred for PSMA or choline PET/CT after radical prostatectomy due to biochemically recurrent or persistent disease. BRFS (PSA: 0.2 ng/mL) was defined as the study endpoint. Cox regression analyses were performed to assess the impact of different clinical parameters on BRFS. Additionally, propensity score matching was performed to adjust patient cohorts (PSMA vs. choline PET/CT-based sRT). The median follow-up time was 30 months. BRFS at three years after sRT was 58%. In the multivariate analysis, only PSA before PET imaging and PSA before sRT were significantly associated with BRFS (p < 0.05). After propensity score matching, 272 patients were further analyzed; there was no significant difference in three-year BRFS between patients with PSMA PET-based vs. choline PET-based sRT (55% vs. 63%, p = 0.197). The present analysis confirmed the overall high BRFS rates after PET-based sRT and the strong prognostic effect of PSA level prior to sRT. PSMA PET-based sRT did not have superior BRFS rates when compared with choline PET-based sRT. MDPI 2020-11-16 /pmc/articles/PMC7698293/ /pubmed/33207785 http://dx.doi.org/10.3390/cancers12113395 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Schmidt Hegemann, Nina-Sophie Rogowski, Paul Eze, Chukwuka Schäfer, Christian Stief, Christian Lang, Sebastian Spohn, Simon Steffens, Rieke Li, Minglun Gratzke, Christian Schultze-Seemann, Wolfgang Ilhan, Harun Fendler, Wolfgang Peter Bartenstein, Peter Ganswindt, Ute Buchner, Alexander Grosu, Anca-Ligia Belka, Claus Meyer, Philipp Tobias Kirste, Simon Zamboglou, Constantinos Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis |
title | Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis |
title_full | Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis |
title_fullStr | Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis |
title_full_unstemmed | Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis |
title_short | Outcome After 68Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis |
title_sort | outcome after 68ga-psma-11 versus choline pet-based salvage radiotherapy in patients with biochemical recurrence of prostate cancer: a matched-pair analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698293/ https://www.ncbi.nlm.nih.gov/pubmed/33207785 http://dx.doi.org/10.3390/cancers12113395 |
work_keys_str_mv | AT schmidthegemannninasophie outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis AT rogowskipaul outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis AT ezechukwuka outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis AT schaferchristian outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis AT stiefchristian outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis AT langsebastian outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis AT spohnsimon outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis AT steffensrieke outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis AT liminglun outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis AT gratzkechristian outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis AT schultzeseemannwolfgang outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis AT ilhanharun outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis AT fendlerwolfgangpeter outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis AT bartensteinpeter outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis AT ganswindtute outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis AT buchneralexander outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis AT grosuancaligia outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis AT belkaclaus outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis AT meyerphilipptobias outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis AT kirstesimon outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis AT zamboglouconstantinos outcomeafter68gapsma11versuscholinepetbasedsalvageradiotherapyinpatientswithbiochemicalrecurrenceofprostatecanceramatchedpairanalysis |